655-796

Principle Routes of Exposure

Inhalation: Yes. Skin: Yes. Ingestion: Yes. Acute Exposure: Inhalation, dermal absorption or ingestion of this product may result in systemic intoxication due to inhibition of the enzyme cholinesterase. The sequence of development of systemic effects varies with the route of entry, and the onset of symptoms may be delayed an hour or more. First symptoms of poisoning may be nausea, increased salivation, lacrimation, blurred vision and constricted pupils. Other symptoms of systemic poisoning include vomiting, diarrhea, abdominal cramping, dizziness and sweating. After inhalation, respiratory symptoms like tightness of chest, wheezing and laryngeal spasms may be pronounced at first. If the poisoning is severe, then symptoms of convulsions, low blood pressure, cardiac irregularities, loss of reflexes and coma may occur. In extreme cases, death may occur due to a combination of factors such as respiratory arrest, paralysis of respiratory muscles or intense bronchoconstrictions. Complete symptomatic recovery from sublethal poisoning usually occurs within 24 hours once the source of exposure is completely removed. The solvents in this product can be irritating to the skin, eyes, nose and throat. In high vapor concentrations, drowsiness can occur. Based on EPA Toxicity Category criteria, this product is moderately toxic orally and minimally toxic dermally. Animal studies have shown that this product is a severe eye irritant and can cause irreversible eye damage. Chronic Exposure: Repeated exposure to small amounts of propoxur may result in an unexpected cholinesterase depression causing symptoms such as malaise, weakness, and anorexia that resemble other illnesses such as influenza. Exposure to the concentration that would not have produced symptoms in a Page - 1 person that was not previously exposed may produce severe symptoms of cholinesterase inhibition in a previously exposed person. High doses of propoxur induced bladder cancers when fed to rats in one study. Cancer was not induced in several other feeding studies on rats and other animals. The implications of these studies for humans are not known. Repeated skin contact with the solvents in this product can cause drying, cracking or irritation of the skin. Carcinogenicity: This product is not listed by NTP, IARC or regulated as a carcinogen by OSHA.

Medical Conditions Generally Aggravated by Exposure

No specific medical conditions are known which may be aggravated by exposure to the active ingredient in this product; however, any disease, medication or prior exposure which reduces normal cholinesterase activity may increase susceptibility to the toxic effects of the active ingredient.